

# Study the Relation between Homocystein and Some Physiological and Oxidative Stress Parameters in Iraqi Diabetics Patients Type2

Saja M. Thakir and Alia H. Ali

University of Baghdad/ College of Science for women/ Department of Biology

**Abstract:** The aim of this study is to explain the effect of type2 DM on the concentration of blood glucose, HbA<sub>1c</sub>, serum uric acid. Lipid profile concentration, Homocysteine (Hcy) concentration, High sensitive CRP (hsCRP) concentration. Oxidative stress parameters that include Lipid peroxidation Malondialdehyde (MDA). Antioxidant parameters that include Glutathione (GSH), water soluble vitamin (vitamin C) and Lipid soluble vitamin (vitamin E). Sixty diabetic patients was used in this study with the range of age from 50 to 69 years from Specialized Center For Endocrine diseases and Diabetes of Baghdad Health Department/Al-Rusafa .This study was included 30 man and 30 woman suffers from diabetes mellitus type 2 , and this samples was divided in to three groups according to the type of treatment they use, group take oral hypoglycemic tab (group A) , group take Insulin (group B) and group take both oral hypoglycemic tab and Insulin (group C).And we take 30 sample it was use as a control group to compare with patients sample. Results explained significantly increases ( $p < 0.05$ ) in F.B.S, HbA<sub>1c</sub>, Hcy and hsCRP concentration as compared with control group, Results showed significant differences in the

concentration of uric acid as compared with control group in Male and Female patients, While the result of Lipid profile concentration showed significant differences as compared with control group. Oxidative stress parameter include MDA showed significantly increases ( $p < 0.05$ ) as compared with control group. While Antioxidant parameters include GSH, vitamin C and vitamin E showed significantly decreases ( $p > 0.05$ ) as compared with control group.

**Keywords:** Diabetes mellitus type2, Homocysteine, high sensitive CRP (hsCRP), Malondialdehyde (MDA), Glutathione (GSH).

## 1. Introduction

Diabetes mellitus is a metabolic disease that affects almost 300 million people worldwide, and this number is expected to approach 450 million by 2030<sup>(1,2)</sup>. Type 2 diabetes is the commonest form of diabetes that associated with multiple metabolic derangements that result in the excessive production of reactive oxygen species (ROS) and oxidative stress<sup>(3)</sup>. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs, that include

retinopathy, nephropathy, angiopathy and atherosclerosis, that impose a tremendous burden on individual with diabetes and on the health care system<sup>(4)</sup>. Patients with type 2 diabetes have a high incidence of atherosclerosis, which leads to increased morbidity and mortality from coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (PVD)<sup>(5)</sup>

Oxidative stress is associated with diabetes, because of excessive production of reactive oxygen species (ROS) and an impaired antioxidant defense mechanism<sup>(6,7)</sup>. The occurrence of free radical induced lipid peroxidation causes considerable changes in the cell membrane<sup>(8)</sup>. Lipid Peroxidation of the lipid membrane has been related to the pathogenesis of many degenerative diseases, such as atherosclerosis, aging, carcinogenesis and diabetes mellitus<sup>(9)</sup>. Lipoprotein abnormalities in patient with diabetes are likely to play important role in development of atherogenesis<sup>(10)</sup>, this abnormalities in

lipoproteins are recognized as predictors for coronary heart disease, including elevated total cholesterol (TC) and Very Low Density Lipoprotein -Cholesterol (VLDL) and a predominance of low density Lipoprotein -Cholesterol (LDL)<sup>(11)</sup>, while reduced plasma levels of high density Lipoprotein -cholesterol (HDL-C) concentration and elevated plasma levels of Triacylglycerol (TAG)<sup>(12'13)</sup>.

Serum uric acid is the final product of purines metabolism, has recently been associated with metabolic syndrome<sup>(14'15)</sup>. Moreover many studies have assessed the association of serum uric acid levels with the incidence of impaired fasting glucose in type 2 diabetes mellitus (T2DM)<sup>(16'17)</sup>, which suggest hyperuricemia to be an early importance indicator of impaired glucose control<sup>(18'19)</sup>.

Glycated haemoglobin (HbA<sub>1c</sub>) is recognized as the best index for long-term glucose control in diabetic patients<sup>(20)</sup> also, it is regarded as a useful screening tool for detecting diabetes in

general population<sup>(21'22)</sup>. HbA<sub>1c</sub> has been found to be associated with atherosclerosis<sup>(23'24)</sup>; incidence of diabetes, cardiovascular disease (CVD)<sup>(25'26)</sup>

Homocysteine (hcy) is a nonessential sulphur-containing amino acid and an intermediary metabolic product derived from the demethylated essential amino acid methionine<sup>(27)</sup>.

Circulating homocysteine derives from the interplay of genetic and environmental factors involved in the homocysteine/methionine metabolic cycle. Ageing and gender, renal function, the status of nutritional coenzymes of vitamin B12, B6 and folate, together with lifestyle factors such as smoking, are known determinants of plasma homocysteine concentration<sup>(28)</sup>. Hyper homocysteinemia (Hhcy) has been associated with pathological and stressful conditions and is a risk factor for Cardiovascular disease (CVD)<sup>(29)</sup> The C-reactive protein being as an acute phase reactant protein that serves as a novel biomarker for inflammation and atherosclerosis.

Generally, it is a risk factor for cardiovascular disease and may specifically predict the development of Myocardial infarction (MI) and stroke in human<sup>(30)</sup>. CRP may cause atherogenesis by the production of oxygen free radicals (ORs) and expression of adhesion molecules. The oxidative theory of atherosclerosis is based upon the pathophysiological generation of ORs<sup>(33)</sup>.

The human body is equipped with a variety of antioxidants that seem to counterbalance the effect of the reactive oxygen species (ROs) these can be divided into two categories enzymatic and nonenzymatic antioxidant, the non-enzymatic antioxidant include Vitamin C , E , uric acid and GSH triple peptide <sup>(32)</sup>. Antioxidants can be defined as substances whose presence in relatively high concentration significantly inhibits the rate of oxidation of lipids, proteins, carbohydrates and DNA. Antioxidants such as uric acid (UA and glutathione GSH) act as potent electron donors; they donate hydrogen

atoms to pair up with unpaired electrons on free radicals. Thus, they convert reactive free radicals into inactive substances<sup>(33)</sup>.

## 2. Subject and method

**Subjects:** This study was carried out at Specialized Center For Endocrine diseases and Diabetes of Baghdad Health Department/Al-Rusafa, from September 2016 to March, 2017. That included 60 diabetic patient (30 are male and 30 female) and this samples was divided in to three groups according to the type of treatment they use, group A take Oral tape, group B take Insulin and group C take both Oral hypoglycemic drug and Insulin. And 30 normal subject as control, all of them in the range of age 50-69 years.

**Blood sample:** Ten milliliter (10 ml) of venous blood sample was taken, using plastic disposable syringes. Two milliliter (2 ml) were added to an ethylene diamine tetra acetic acid (EDTA) tube for Hemoglobin A<sub>1C</sub> measuring, The remaining 8 ml of the blood were transferred to disposable plain tube. The

serum was separated by centrifugation at 3000 rpm for 5 minutes, and collected in plain tube and kept frozen at (-20°C) until assayed. Each serum sample was analyzed for Glucose, Lipid profile, uric acid and Homocysteine, High sensitive CRP(hsCRP), Malondialdehyde (MDA), Glutathione (GSH), Vitamin C&E .

**Methods:** Fasting Blood Sugar was measured according to Thomas<sup>(34)</sup>. Uric acid was measured by colorimetric method Thomas<sup>(34)</sup>. Measurement of glycosylated hemoglobin A1c (HbA1c) according to Baynes, et al.<sup>(35)</sup>.

Measurement of Lipid profile, Serum total cholesterol (TC), Triacylglycerol (TAG) determined according to enzymatic colorimetric method Thomas,<sup>(34)</sup> High Density Lipoprotein (HDL -C) concentration measured according to Tietz,<sup>(36)</sup>, Estimation of (LDL -C) by the following equation according to Friedewald, et al.<sup>(37)</sup>.  $LDL -C = TC - (HDL -C + VLDL -C)$ , and Very Low Density Lipoprotein (VLDL -C) concentration that was



estimated by the following equation according to Friedewald, *et al.*,<sup>(37)</sup> 
$$\text{VLDL } -C = \text{TAG} / 5.$$
 Measurement of serum Homocysteine was performed using sandwich enzyme immune assay technique kit was measured according to Upchurch *et al.*<sup>(38)</sup>.

Measurement of High sensitive CRP protein (hsCRP) by using ichroma<sup>1m</sup>hsCRP by using sandwich immunofluorescence assay, reader analyzes and reads the fluorescence intensity the CRP concentration I sample Oh SW *et al.*<sup>(39)</sup>.

Measurement of Malondialdehyde (MDA) according to Burtis & Ashwood<sup>(40)</sup>. Serum Glutathione (GSH) measured according to Ellman<sup>(41)</sup>.

Serum vitamin C and vitamin E measured by using sandwich enzyme immune assay technique according to Lin<sup>(42)</sup>, Bieri, *et al.*<sup>(43)</sup>.

### 3. Result

The results of Fasting blood sugar and HbA1C for type 2 diabetes mellitus showed higher significant difference ( $p < 0.05$ ) in Male and Female diabetics groups when compared to the healthy controls.

Table (1): Explain the effect of Diabetes mellitus type 2 on Fasting blood sugar (FBS) and Glycosylated hemoglobin A1c (HbA<sub>1c</sub>) in Male and Female.

FBS  HbA <sub>1c</sub>		Mean ± SE				LSD value
		Control	group A Oral tab	group B Insulin	group C tab +Insulin	
Male	FBS (mmol/L)	5.62 ± 0.62 b	13.43 ± 3.13 a	13.13 ± 2.42 a	11.85 ± 4.41 a	2.564*
Female		7.64 ± 3.53 c	10.48 ± 2.94 b	10.20 ± 1.56 a	13.13 ± 2.55 a	
Male	HbA <sub>1c</sub> (mg/dL)	4.89 ± 0.56 b	11.50 ± 1.47 a	11.63 ± 2.33 a	9.13 ± 2.12 a	3.073*
Female		4.53 ± 0.31 b	9.23 ± 1.65 a	9.45 ± 1.52 a	11.67 ± 2.05 a	
*( $p < 0.05$ ).						

FSB = Fasting Blood Sugar, Mean ± SE = Mean ± Slandered error.

LSD = Less significant differences, HbA<sub>1c</sub> = Hemoglobin A<sub>1c</sub>.

serum uric acid concentration showed significant differences ( $p < 0.05$ ) in Male and Female diabetics groups when compared with healthy control group.

Table (2): Explain the effect of Diabetes mellitus type 2 on serum Uric acid in Male and Female.

Uric acid		Mean ± SE				LSD value
		Control	group A Oral tab	group B Insulin	group C tab +Insulin	
Male	Uric acid ( $\mu\text{mol/L}$ )	338.57 ± 31.53 a	282.4 ± 51.79 b	342.54 ± 62.84 a	363.00 ± 13.22a	39.67*
Female		275.60 ± 33.60 a	260.4 ± 50.36 a	266.18 ± 72.92 a	192.00 ± 11.63b	45.09*
*( $p < 0.05$ ).						

Mean ± SE = Mean ± Standard error.

LSD = Less significant differences.

Serum total Cholesterol (TC) result showed non-significant differences ( $p > 0.05$ ) between diabetic groups in Male and Female with healthy control group. Serum Triacylglycerol (TAG) results explained significant increases ( $p < 0.05$ )

between diabetics groups among Male and Female compared with healthy control group. High Density Lipoprotein Cholesterol (HDL-C) results showed non-significant differences ( $p > 0.05$ ) in Male groups as compared with control group. While the results of High Density Lipoprotein Cholesterol (HDL-C) in Female groups showed significant differences ( $p < 0.05$ ) as compared with control group. Low Density Lipoprotein (LDL-C) results showed significant differences ( $p < 0.05$ ) in Male groups as compared with control group. While the results of Low Density Lipoprotein in Female groups showed non-significant differences ( $p > 0.05$ ) as compared with control group.

Table (3): Explain the effect of Diabetes mellitus type2 on Lipid profile in both Male and Female.

Lipid Profile	Mean ± SE				LSD value
	Control	group A Oral tab	group B Insulin	group C tab +Insulin	

<b>Male</b>	<b>cholesterol (mmol/L)</b>	4.59 ± 0.63 a	4.42 ± 0.75 a	4.05 ± 0.62 a	4.10 ± 0.75 a	0.772  <b>NS</b>
<b>Female</b>		5.19 ± 0.52 a	4.51 ± 0.78 a	4.82 ± 0.49 a	4.93 ± 0.73 a	0.630  <b>NS</b>
<b>Male</b>	<b>Triglyceride (mmol/L)</b>	2.285 ± 0.44 c	3.02 ± 0.92 b	2.41 ± 0.45 c	3.55 ± 2.28 a	0.334*
<b>Female</b>		1.86 ± 0.63 b	1.77 ± 0.23 b	2.53 ± 0.60 a	2.90 ± 1.09 a	0.405*
<b>Male</b>	<b>HDL (mmol/L)</b>	1.014 ± 0.08 a	0.806 ± 0.12 a	0.911 ± 0.23 a	0.925 ± 0.15 a	0.338  <b>NS</b>
<b>Female</b>		1.846 ± 0.79 a	1.05 ± 0.18 b	1.036 ± 0.22 b	1.10 ± 0.12 b	0.462*
<b>Male</b>	<b>LDL (mmol/L)</b>	3.12 ± 0.72 a	3.20 ± 0.52 a	2.74 ± 0.23 b	2.47 ± 0.16 b	0.478*
<b>Female</b>		2.97 ± 1.07 a	3.11 ± 0.75 a	3.28 ± 0.42 a	3.25 ± 0.63 a	0.361  <b>NS</b>
<b>Male</b>	<b>VLDL (mmol/L)</b>	0.457 ± 0.08 b	0.610 ± 0.04 ab	0.482 ± 0.07 b	0.710 ± 0.44 a	0.269*
<b>Female</b>		0.372 ±	0.353 ±	0.505	0.580 ±	0.275

		0.10 a	0.04 a	±	0.22	NS
				0.11 a	a	

Mean ± SE = Mean ± Standard error.

LSD = Least significant differences.

Results of Homocysteine (Hcy) showed significant increases ( $p < 0.05$ ) between diabetic groups among Male and Female with healthy control group. The result of High sensitive C-Reactive protein (hsCRP) showed significant differences ( $p < 0.05$ ) in Male and Female as compared with control group. Malondialdehyde (MDA) result showed significant decrease ( $p < 0.05$ ) in Male and Female as compared with control group.

Table (4): Explain the effect of Diabetes mellitus type 2 on Homocysteine (Hcy), High sensitive CRP (hsCRP) and Malondialdehyde (MDA).

		Mean ± SE				LSD value
		Control	group A Oral tab	group B Insulin	group C tab +Insulin	
<b>Homocysteine High Sensitive CRP (hsCRP) Malondialdehyde (MDA)</b>						
<b>Male</b>	<b>Hcy (µmol/L)</b>	4.45 ± 0.22 b	10.07 ± 0.63 a	9.14 ± 0.75 a	10.37 ± 0.62 a	2.622*
<b>Female</b>		3.79 ± 0.28 b	9.59 ± 0.55 a	8.99 ± 0.64 a	8.00 ± 0.23 a	2.705*
<b>Male</b>	<b>hsCRP (mg/dL)</b>	2.001 ± 0.22 b	9.05 ± 2.27 a	8.60 ± 1.45 a	8.03 ± 1.03 a	2.308*
<b>Female</b>		2.023 ± 0.17 c	9.16 ± 1.07 a	6.83 ± 1.23 b	5.70 ± 0.64 b	2.641*
<b>Male</b>	<b>MDA (µmol/L)</b>	1.08 ± 0.08 b	2.60 ± 0.33 a	2.57 ± 0.29 a	2.24 ± 0.17 a	0.533*
<b>Female</b>		1.25 ± 0.11 c	2.74 ± 0.23 ab	2.48 ± 0.24 b	3.00 ± 0.33 a	0.427*

Mean ± SE = Mean ± Slandered error.

LSD = Less significant differences.

Results of Glutathione (GSH) showed significant decreases ( $p > 0.05$ ) in Male and Female as compared with control group, Also the results of Vitamin C explained significant decreases ( $p > 0.05$ ) in Male and Female as compared with control group and the results of Vitamin E revealed significant decreases ( $p > 0.05$ ) in Male and Female as compared with control group.

		Mean $\pm$ SE				LSD value
		Control	group A Oral tab	group B Insulin	group C tab +Insulin	
Male	GSH ( $\mu\text{mol/L}$ )	3.52 $\pm$ 0.33 a	1.371 $\pm$ 0.15 b	1.482 $\pm$ 0.12 b	1.427 $\pm$ 0.09 b	0.853*
		Female	3.69 $\pm$ 0.31 a	1.415 $\pm$ 0.06 b	1.523 $\pm$ 0.12 b	
Male	Vit.C (mg/dL)	1.71 $\pm$ 0.18 a	0.691 $\pm$ 0.07 b	0.735 $\pm$ 0.08 b	0.642 $\pm$ 0.06 b	0.304*
Female		1.63 $\pm$ 0.21 a	0.710 $\pm$ 0.08 b	0.702 $\pm$ 0.08 b	0.680 $\pm$ 0.05	0.452*



					<b>b</b>	
<b>Male</b>	<b>Vit.E (mg/dL)</b>	0.872 ± 0.09 a	0.360 ± 0.04 b	0.445 ± 0.06 b	0.357 ± 0.07 <b>b</b>	0.229*
<b>Female</b>		0.987 ± 0.13 a	0.396 ± 0.06 b	0.490 ± 0.05 b	0.340 ± 0.04 <b>b</b>	0.317*

#### 4. Discussion

This study was based on the relation between some of physiological and oxidative stress parameters among diabetics patients type 2, In this study there is significant increases observed in glucose concentration in diabetic groups as compared with control group, this results agree with Suwanto et al.<sup>(44)</sup>. The HbA1c has been used as an objective marker of average glycemic control because the levels of HbA1c in the blood reflect the glucose levels which erythrocyte has been exposed during its lifespan<sup>(45)</sup>. HbA1c concentration in this study showed significant increases in male and female agree

with results obtained by Nada & Abdul Jalil<sup>(46)</sup>. Serum Uric acid is produced by the metabolism of nitrogen bases (Purine), and is considered as a risk factor for diabetes complication. In the study there is significant increases in Male and Female this results agree with Hayden & Tyagi<sup>(47)</sup>, Increases in the concentration of uric acid is a well-known abnormality observed in diabetic patient<sup>(48)</sup>.

Patients with type 2 diabetes frequently have an abnormal blood lipid profile consisting of elevated LDL-C, and triglycerides with decrease in HDL-C. The result of the present study showed non-significant differences in total cholesterol concentration, and increases ( $p < 0.05$ ) in Triacylglycerol concentration with significant increases ( $p < 0.05$ ) in Low density Lipoprotein (LDL-C) among Male patient compared with control group, but there is non-significant differences among Female patient compared with control group, while there is non-significant differences in High Density Lipoprotein (HDL-C) among Male patient compared with control group, but there is significant decreases ( $p > 0.05$ ) in High Density Lipoprotein (HDL-C) among Female patient compared with control group. Very Low Density Lipoprotein (VLDL -C) in Male diabetic patient there was significant increase ( $p < 0.05$ ) as compared with control group, while there was non-significant differences in Female diabetic patient as compared

with control group. This result agreement with Finch et al.<sup>(49)</sup>. Hypercholesterolemia and Hypertriglyceridemia were associated with oxidative modification of LDL-C, protein glycation and glucose auto oxidation, thus leading to excess production of lipid peroxidation products which may cause elevation of oxidative stress in higher lipid and hyperlipidemic subjects<sup>(50)</sup>. Oxidative stress was indicated by increased free radicals production, the generation of free radicals may lead to lipid peroxidation and the formation of several types of damage in diabetes mellitus patient. In this study we observed that a lipid peroxidation product, MDA level as a marker of oxidative stress, were elevated significantly in diabetic patients in both Male and Female. Similar result were observed by Mahboob<sup>(51)</sup>. Oxidative stress linked to cardiovascular disease due to oxidation of LDL-C in vascular endothelium is a precursor to plaque formation. Oxidative stress also play a role in the ischemic caused due to oxygen reperfusion injury following hypoxia that include strokes

and heart attacks, oxidative stress has been implicated in chronic fatigue syndrome<sup>(52)</sup>, that contributes to tissue injury in many condition one of them Diabetes mellitus.

Homocysteine concentration in type2 diabetics patients significantly increase in Male and Female group compared with its concentration in control group this result corresponds with the result of Moselhy&Demerdash<sup>(53)</sup>. Hyperglycemia in type2 diabetics patient causes abnormal lipids, carbohydrates and proteins metabolisms which may leads to abnormal elevated homocysteine concentration, also some medications which is used in great number of diabetics is known to cause vitamins B12 and folate deficiencies that causes consequently leads to hyperhomocysteinemia<sup>(54)</sup>. Many studies have shown that Hcy acts on the cardiovascular system with a direct toxicity on the endothelium and increase in vascular smooth muscle cells inducing its proliferation, enhance collagen production<sup>(55)</sup>.

The study showed significantly increase ( $p < 0.05$ ) in the concentration of High sensitive C-Reactive Protein (hsCRP) among diabetic group this result comparable with the result present by Al-Thanoon & Mahmood<sup>(56)</sup>. Oxidative stress play a multiple role in the inflammatory response by Cytokine – related ROS release and by regulation of transcription factors its proinflammatory cytokine especially IL6, IL -1 $\beta$  and TNF - $\alpha$  produced by monocyte and the acute phase reactant CRP protine released in response to ROS and also important in plug formation<sup>(57)</sup>. Homocysteine and hsCRP which both indicates the role of oxidative stress and inflammation in atherosclerosis<sup>(58)</sup>.

Products of lipid peroxidation such as MDA are capable of inactivating many cellular proteins by forming protein cross linkage<sup>(59)</sup>. Lipid peroxidation products MDA it used as abiomarkers of oxidative stress. This study showed significantly increase in the MDA concentration of diabetics patient

compared with control group. This result agreed with the result submitted by Varashree & Bhat<sup>(60)</sup>. MDA considered as an important indicator for evaluating oxidative stress in degenerative diseases like diabetes mellitus. The elevated in the MDA level indicated that any oxidative stress incurred sufficiently cause of free radical mediated peroxidation of lipid components in cell membrane, which lead to the damage of the cell<sup>(61)</sup>

The study showed significant decreases ( $p > 0.05$ ) in GSH concentration in Male and Female diabetic patient as compared with control group.

GSH is important for the protection of cell membrane from lipid peroxidation and protect lipids from oxidant attacks<sup>(62)</sup>. These result agree with our results that the concentration of GSH decreased significantly in diabetic patient, low GSH level in red blood cells reflects generalized decrease in intracellular content of this compound. Similar result was obtained by Livingstone & Davis<sup>(63)</sup>. These results indicate

that patients with type 2 diabetes have lower concentration of intracellular GSH, which increases the susceptibility of cells to the damaging effects of RO

The present study showed significant decreases ( $p > 0.05$ ) in vitamin C concentration in diabetic patient as compared with control group in Male and Female, The result obtained in these study agree with Tarnag et al.<sup>(64)</sup>. Also the result of vitamin E showed significant decreases ( $p > 0.05$ ) in diabetic patient as compared with control group in Male and Female, Vitamin E (Alph -Tocopherol) has a biochemical efficacy in beneficially altering the biomarkers of oxidative stress and in increasing erythropoiesis or reducing the required dose of erythropoietin. Also vitamin E may help stabilize atherosclerotic plug<sup>(65)</sup>.

## Conclusion

1. Diabetes mellitus considered as a chronic disease cause they affects the lives of millions of people around the

world, and generally concenter as an oxidative stress disease .

2. Elevated homocysteine level as one of diabetes mellitus type2 complications, that concenter as a risk factor for CVD, also the increase level of (hsCRP)concenter as specific parameters for Heart disease.
3. Increase in the level of some oxidative stress parameters such as(Glucose ,HbA1c, Lipid profile, Uric acid and MDA) as an expected result from diabetic complication.
4. Decreases in the level of antioxidant defense (GSH, Vit C and Vit E) .

## References

1. Atlas, D. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015.
2. Wild, S. H., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections



for 2030: response to Rathman and Giani. *Diabetes care*, 27(10), 2569-2569.

3. Kumawat, M., Singh, I., Singh, N., Singh, V., &Kharb, S. (2012). Lipid peroxidation and lipid profile in type II diabetes mellitus.
4. American Diabetes Association. (2014). Diagnosis and classification of diabetes mellitus. *Diabetes care*, 37(Supplement 1), S81-S90.
5. Premalatha, G., Shanthirani, S., Deepa, R., Markovitz, J., & Mohan, V. (2000). Prevalence and risk factors of peripheral vascular disease in a selected South Indian population: the Chennai Urban Population Study. *Diabetes care*, 23(9), 1295-1300.
6. Ceriello, A., &Motz, E. (2004). Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. *Arteriosclerosis, thrombosis, and vascular biology*, 24(5), 816-823.

7. Laudat, A., Lecourbe, K., Guéchet, J., & Palluel, A. M. (2002). Values of sperm thiobarbituric acid-reactive substance in fertile men. *Clinica Chimica Acta*, 325(1), 113-115.
8. Rahimi, R., Nikfar, S., Larijani, B., & Abdollahi, M. (2005). A review on the role of antioxidants in the management of diabetes and its complications. *Biomedicine & Pharmacotherapy*, 59(7), 365-373.
9. Nair, U., Bartsch, H., & Nair, J. (2007). Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. *Free Radical Biology and Medicine*, 43(8), 1109-1120.
10. Stocker, R., & Keaney, J. F. (2004). Role of oxidative modifications in atherosclerosis. *Physiological reviews*, 84(4), 1381-1478.
11. Hashim, D. A. (2015). Serum Lipid Profiles in Hypertensive Diabetes Mellitus Type 2 Patients. *A, a*, 151, 6-81.
12. Otamere, H. O., Aloamaka, C. P., Okokhere, P. O., & Adisa, W. A. (2011). Lipid profile in diabetes mellitus; what impact has age and

duration. *British Journal of Pharmacology and Toxicology*, 2(3), 135-137.

13. Layman, D. K., Boileau, R. A., Erickson, D. J., Painter, J. E., Shiue, H., Sather, C., & Christou, D. D. (2003). A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women. *The Journal of nutrition*, 133(2), 411-417.

14. Tsouli, S. G., Liberopoulos, E. N., Mikhailidis, D. P., Athyros, V. G., & Elisaf, M. S. (2006). Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. *Metabolism*, 55(10), 1293-1301.

15. de Oliveira, A., Miranda Hermsdorff, H. H., GuedesCocate, P., Bressan, J., AzevedoNovello, A., Cardoso dos Santos, E., & Natali, A. J. (2014). The impact of serum uric acid on the diagnostic of metabolic syndrome in apparently healthy Brazilian middle-aged men. *NutricionHospitalaria*, 30(3).

16. Teng, F., Liang, J., Zou, C. Y., Qi, L., & Song, H. D. (2010). Serum uric acid and prehypertension among Chinese adults. *Zhonghuaneikezazhi*, 49(11), 921-924.
17. Chu, N. F., Wang, D. J., Liou, S. H., & Shieh, S. M. (2000). Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. *European journal of epidemiology*, 16(1), 13-17.
18. Verdoia, M., Barbieri, L., Schaffer, A., Casetti, E., Nardin, M., Bellomo, G., ... & Novara Atherosclerosis Study Group. (2014). Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: A single-centre cohort study. *Metabolism*, 63(5), 640-646.
19. Cicero, A. F. G., Derosa, G., Rosticci, M., D'Addato, S., Agnoletti, D., Borghi, C., & Brisighella Heart Study group. (2014). Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the

Brisighella Heart Study historical cohort. Diabetes research and clinical practice, 104(1), 183-188.

20. Jeffcoate, S. L. (2004). Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabetic Medicine, 21(7), 657-665.
21. Bennett, C. M., Guo, M., & Dharmage, S. C. (2007). HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabetic medicine, 24(4), 333-343.
22. International Expert Committee. (2009). International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes care, 32(7), 1327-1334.
23. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813-820.
24. Jørgensen, L., Jenssen, T., Joakimsen, O., Heuch, I., Ingebretsen, O. C., & Jacobsen, B. K. (2004). Glycated hemoglobin level is strongly

related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals. *Circulation*, 110(4), 466-470.

25. Khaw, K. T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day,

N. (2004). Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. *Annals of internal medicine*, 141(6), 413-420.

26. Syed, I. A. A., & Khan, W. A. (2011). Glycated haemoglobin—a marker

and predictor of cardiovascular disease. *JPMA-Journal of the Pakistan Medical Association*, 61(7), 690.

27. Tutuncu, N. B., Erbas, T., Alikasifoglu, M., & Tuncbilek, E. (2005).

Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels. *Journal of internal medicine*, 257(5), 446-453.

28. Russo, G. T., Di Benedetto, A., Giorda, C., Alessi, E., Crisafulli, G.,

lentile, R., ... & Cucinotta, D. (2004). Correlates of total

homocysteine plasma concentration in type 2 diabetes. *European journal of clinical investigation*, 34(3), 197-204.

29. Austin, R. C., Lentz, S. R., & Werstuck, G. H. (2004). Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell Death & Differentiation*, 11, S56-S64.
30. Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006). C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. *Journal of the American College of Cardiology*, 47(8), C19-C31.
31. Prasad, K. (2000). Oxygen free radicals and peripheral vascular disease. In *Textbook of Angiology* (pp. 427-438). Springer, New York, NY.
32. Drożdż, D., Kwinta, P., Sztefko, K., Kordon, Z., Drożdż, T., Łątka, M., ... & Pietrzyk, J. A. (2016). Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. *Oxidative medicine and cellular longevity*, 2016.

33. Palmieri, B., & Sblendorio, V. (2007). Oxidative stress tests: overview on reliability and use. *European review for medical and pharmacological sciences*, 11(6), 383-399.
34. Thomas, L. (1998). *Clinical Laboratory Diagnostic*. 1<sup>st</sup> ed. Frankfurt : TH-Books verlagsgesellschaft. PP 36-46, 55-65, 208-214, 241-247, 374-377.
35. Baynes, J. W., Thorpe, S. R., & Murtiashaw, M. H. (1984). [8] Nonenzymatic glucosylation of lysine residues in albumin. *Methods in enzymology*, 106, 88-98.
36. Tietz, N. W. (1983). *Clinical Guide to Laboratory Tests*. W. B. Saunders. Company. Philadelphia, PP 152-154.
37. Friedewald, W.; Levy, Y. and Fredrickson, A. (1972). Estimation of the concentration of low – density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. *Clin. Chem.*, 18:499-502.



38. Upchurch GR, Jr., Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, and Loscalzo J. (1997). Measurements of homocysteine. *J. Biol Chem* 272:17012-17017.
39. Oh SW, Moon JD, Park SY, et al. Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing. *Clin Chim Acta* 2005; 356:172-177.
40. Burtis, C. A. and Ashwood, E. R. (1999). *Tietz Textbook of clinical chemistry*. 3<sup>rd</sup> ed. Philadelphia. W. B. Saunders Company. PP 671-1270, 1838.
41. Ellman GL. (1959). Measurement of reduced glutathione by colorimetric method. *Arch Biochem Biophys*: 70, 82-87. *Endocr Rev*. 2002; 23:599-622.
42. Lin p. (1982). Determination of vitamin C by Spectrophotometer method. *Clin Chem*. 28; P: 2225-2228.

43. Bieri, J. G., Tolliver, T. J., & Catignani, G. L. (1979). Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. *The American Journal of Clinical Nutrition*, 32(10), 2143-2149.
44. Suwanto, S., Sutrisna, B., Waspadji, S., & Pohan, H. T. (2014). Predictors of five days mortality in diabetic ketoacidosis patients: a prospective cohort study. *Acta Medical Indonesiana*, 46(1).
45. Mehta, P. K., & Griending, K. K. (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *American Journal of Physiology-Cell Physiology*, 292(1), C82-C97.
46. Nada, S., & Abdul Jalil, F. (2010). Serum levels of Interleukin 6 and Homocysteine in Type 2 Diabetic Patients with renal failure complication. *Karbala Journal Med*, 3(1).
47. Hayden, M. R., & Tyagi, S. C. (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type

2 diabetes mellitus: The urate redox shuttle. Nutrition & metabolism, 1(1), 10.

48. Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J., & Parving, H. H. (2009). Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes. *Diabetes*, 58(7), 1668-1671.
49. Finch, W., Shamsa, K., & Lee, M. S. (2014). Cardiovascular complications of radiation exposure. *Rev Cardiovasc Med*, 15(3), 232-244.
50. Al-Rawi, N. H. (2011). Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. *Diabetes and Vascular Disease Research*, 8(1), 22-28.
51. Mahboob, M., Rahman, M. F., & Grover, P. (2005). Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. *Singapore medical journal*, 46(7), 322.

52. Nijs, J., Meeus, M., & De Meirleir, K. (2006). Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications. *Manual therapy*, 11(3), 187-191.
53. Moselhy, S. S., & Demerdash, S. H. (2003). Plasma homocysteine and oxidative stress in cardiovascular disease. *Disease markers*, 19(1), 27-31.
54. Champe, P., & Harvey, R. (2008). *Biochemistry. Lippincott's Illustrated Reviews 4th ed.*
55. Salehpour, S. (2011). Evaluation of homocysteine levels in patients with polycystic ovarian syndrome. *International journal of fertility & sterility*, 4(4), 168.
56. Al-Thanoon, Z. A. M., & Mahmood, I. H. (2013). Metabolic changes caused by first generation antipsychotic versus second generation antipsychotic in schizophrenic patients. *Journal of Pharmacy Research*, 7(6), 468-471.
57. Descamps-Latscha, B., Drüeke, T., & Witko-Sarsat, V. (2001, May). Dialysis-induced oxidative stress: biological aspects, clinical

consequences, and therapy. In *Seminars in dialysis* (Vol. 14, No. 3, pp. 193-199). Blackwell Science Inc.

58. Gosmanova, E. O., & Le, N. A. (2011). Cardiovascular complications in CKD patients: role of oxidative stress. *Cardiology research and practice*, 2011.

59. Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012). Oxidative stress and antioxidant defense. *World Allergy Organ J* 5: 9–19.

60. Varashree, B. S., & Bhat, G. P. (2011). Correlation of lipid peroxidation with glycated haemoglobin levels in diabetes mellitus. *Online journal of health and allied sciences*, 10(2).

61. Masella, R., Di Benedetto, R., Vari, R., Filesi, C., & Giovannini, C. (2005). Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. *The Journal of nutritional biochemistry*, 16(10), 577-586.

62. Girotti, A. W. (2001). Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. *Journal of Photochemistry and Photobiology B: Biology*, 63(1), 103-113.
63. Livingstone, C., & Davis, J. (2007). Targeting therapeutics against glutathione depletion in diabetes and its complications. *The British Journal of Diabetes & Vascular Disease*, 7(6), 258-265
64. Tarng, D. C., Liu, T. Y., & Huang, T. P. (2004). Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. *Kidney international*, 66(2), 820-831.
65. Himmelfarb, J., & Hakim, R. M. (2003). Oxidative stress in uremia. *Current opinion in nephrology and hypertension*, 12(6), 593-598.